Skip to main content


Relapse prevention long-acting treatment for schizophrenia

Monthly and every-two months subcutaneous risperidone for treatment of schizophrenia, UZEDY is the first treatment based on BEPO® technology approved by the U.S. FDA. UZEDY has been distributed since May 2023 in the United States by Teva (BEPO® technology is licensed to Teva under the name SteadyTeq™).

Strong differentiation thanks to BEPO®

A treatment with options

One injection every 1 or 2 months and no additional starter doses or extra pills once you start UZEDY

Small needle size

One of the smallest LAI needles used to treat schizophrenia

Injected just below the skin

Most other schizophrenia LAIs are injected into muscle

Prefilled syringe

Ready- and easy-to-use, no reconstitution needed

News related to UZEDY®


BEPO® technology